FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

FDA, CBP Seize Counterfeit Weight Loss Drugs

Media reports indicate that FDA and Customs and Border Protection intercepted $270,000 worth of counterfeit and unapproved weight loss drugs in Cincin...

latest-news-card-1
Medical Devices

Piur Device Converting 2D Scans to 3D Cleared

FDA clears a Piur Imaging 510(k) for the Piur tUS Infinity that transforms existing 2D ultrasound devices into advanced 3D imaging systems for thyroid...

latest-news-card-1
Human Drugs

Lilly Sues FDA Over Retatrutide Designation

Lilly asks an Indiana federal court to overturn an FDA determination that the companys retatrutide is a drug rather than a biologic.

latest-news-card-1
Federal Register

Workshop on Live Biotherapeutics for Enterocolitis

Federal Register notice: FDA, CDC, and NIH announce an 11/25 public workshop entitled Live Biotherapeutic Products to Prevent Necrotizing Enterocoliti...

latest-news-card-1
Human Drugs

More Support for Treating All Biologics the Same

Two drug trade associations support an FDA approach to postapproval manufacturing changes in biosimilar and interchangeable biosimilar products.

latest-news-card-1
Human Drugs

FDA OKs AZs Tagrisso Lung Cancer Drug

FDA approves AstraZenecas Tagrisso for some non-small cell lung cancers.

latest-news-card-1
Federal Register

Regulatory Review Period for Ojjaara

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for GlaxoSmithKlines Ojjaara (momelotinib).

latest-news-card-1
Human Drugs

Treat all Biologics the Same: Stakeholders

Two stakeholders say it is important that FDA state that principles in a question-and-answer guidance on pre-approval manufacturing changes to biosimi...

latest-news-card-1
Human Drugs

House Passes Pediatric/Rare Disease Bill

The U.S. House of Representatives passes the Give Kids a Chance Act (HR 3433) that is intended to address childhood cancer and rare diseases.

latest-news-card-1
Human Drugs

Eisai Facility FDA-483 Out

FDA releases the form FDA-483 issued following a 2023 inspection at an Eisai drug manufacturing facility in Gifu, Japan.